

1P-152-T025

Monoclonal Antibody to CD134 Phycoerythrin (PE) conjugated (25 tests)

Clone:	Ber-ACT35
lsotype:	Mouse IgG1
Specificity:	The mouse monoclonal antibody Ber-ACT35 (also known as ACT35) recognizes CD134 (TNFRSF4, OX40), an approximately 50 kDa type I transmembrane glycoprotein expressed on activated T cells. HLDA VI: WS Code C-31
Regulatory Status:	RUO
Immunogen:	HTLV 1-transformed HUT-102 cells
Species Reactivity:	Human, Non-Human Primates
Preparation:	The purified antibody is conjugated with R-Phycoerythrin (PE) under optimum conditions. The conjugate is purified by size-exclusion chromatography and adjusted for direct use. No reconstitution is necessary.
Storage Buffer:	The reagent is provided in stabilizing phosphate buffered saline (PBS) solution containing 15mM sodium azide.
Storage / Stability:	Store in the dark at 2-8°C. Do not freeze. Avoid prolonged exposure to light. Do not use after expiration date stamped on vial label.
Usage:	The reagent is designed for Flow Cytometry analysis of human blood cells using 10 μ I reagent / 100 μ I of whole blood or 10 ⁶ cells in a suspension. The content of a vial (0.25 mI) is sufficient for 25 tests.
Expiration:	See vial label
Lot Number:	See vial label
Background:	CD134 (TNFRSF4, also known as OX40) is a type I transmembrane glycoprotein of TNF/NGF receptor family expressed on activated T cells, fibroblasts, and hematopoietic precursors. Binding to its ligand (OX40L, TNFSF4) on antigen presenting cells gives to the T cell costimulatory signal, and this interaction results also in B cell proliferation and influences T cell memory pool. CD134 is upregulated at sites of inflammation, especially in case of multiple sclerosis and psoriatic lesions.

For laboratory research only, not for drug, diagnostic or other use.



Antibodies References:

*Tanijiri T, Shimizu T, Uehira K, Yokoi T, Amuro H, Sugimoto H, Torii Y, Tajima K, Ito T, Amakawa R, Fukuhara S: Hodgkin's reed-sternberg cell line (KM-H2) promotes a bidirectional differentiation of CD4+CD25+Foxp3+ T cells and CD4+

cytotoxic T lymphocytes from CD4+ naive T cells. J Leukoc Biol. 2007 Sep;82(3):576-84. *Willett BJ, McMonagle EL, Ridha S, Hosie MJ: Differential utilization of CD134 as a functional receptor by diverse strains of feline immunodeficiency virus. J Virol. 2006 Apr;80(7):3386-94.

*Li M, Zhang Y: The effect of anti-human CD134 monoclonal antibody on phytohemagglutinin-induced mRNA expression of perforin in peripheral blood mononuclear cells. Cell Mol Immunol. 2005 Dec;2(6):467-71.

*Voo KS, Bover L, Harline ML, Vien LT, Facchinetti V, Arima K, Kwak LW, Liu YJ: Antibodies targeting human OX40 expand effector T cells and block inducible and natural regulatory T cell function. J Immunol. 2013 Oct 1;191(7):3641-50.

*Endl J, Rosinger S, Schwarz B, Friedrich SO, Rothe G, Karges W, Schlosser M, Eiermann T, Schendel DJ, Boehm BO: Coexpression of CD25 and OX40 (CD134) receptors delineates autoreactive T-cells in type 1 diabetes. Diabetes. 2006 Jan;55(1):50-60.

*Aten J, Roos A, Claessen N, Schilder-Tol EJ, Ten Berge IJ, Weening JJ: Strong and selective glomerular localization of CD134 ligand and TNF receptor-1 in proliferative lupus nephritis. J Am Soc Nephrol. 2000 Aug;11(8):1426-38.

*Jones D, Fletcher CD, Pulford K, Shahsafaei A, Dorfman DM: The T-cell activation markers CD30 and OX40/CD134 are expressed in nonoverlapping subsets of peripheral T-cell lymphoma. Blood. 1999 May 15;93(10):3487-93.

Unless indicated otherwise, all products are For Research Use Only and not for diagnostic or therapeutic use. Not for resale or transfer either as a stand-alone product or as a component of another product without written consent of EXBIO. EXBIO will not be held responsible for patent infringement or other violations that may occur with the use of our products. All orders are accepted subject to EXBIO's term and conditions which are available at www.exbio.cz.

For laboratory research only, not for drug, diagnostic or other use.